CD8A and neoplasm: To address this possibility, we performed an in vitro T cell‐mediated tumor cell killing assay to assess if 6J1 might increase CD8+ T cell‐mediated cytotoxicity against 4T1 mouse mammary carcinoma cells in vitro.